Improvement of liver function tests by antidiabetic agents: The need for multidirectional analysis

Diabetes and Metabolism

Volumn 42, Issue 1, 2016, Pages 1-3

  Verges B ^a,b   Petit, J M ^a,b   Bouillet, B ^a,b  

^a DIJON UNIVERSITY HOSPITAL   (France)

^b INSERM   (France)

Author keywords

Antidiabetic agents; Fatty liver; Liver function

Indexed keywords

ADIPONECTIN; ALANINE AMINOTRANSFERASE; ANTIDIABETIC AGENT; ASPARTATE AMINOTRANSFERASE; CANAGLIFLOZIN; FATTY ACID; GAMMA GLUTAMYLTRANSFERASE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; METFORMIN; PIOGLITAZONE; PLACEBO; SITAGLIPTIN; SULFONYLUREA; TETRAHYDROLIPSTATIN; 2,4 THIAZOLIDINEDIONE DERIVATIVE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIINFLAMMATORY ACTIVITY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; CLINICAL TRIAL (TOPIC); CONTROLLED CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; DRUG EFFECT; EDITORIAL; FATTY ACID OXIDATION; FATTY LIVER; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID STORAGE; LIVER FIBROSIS; LIVER FUNCTION TEST; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OUTCOME ASSESSMENT; STOMACH BYPASS; WEIGHT REDUCTION; DIABETES MELLITUS, TYPE 2; LIVER;

DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; LIVER; LIVER FUNCTION TESTS; THIAZOLIDINEDIONES;

EID: 84949647875     PISSN: 12623636     EISSN: 18781780     Source Type: Journal    
DOI: 10.1016/j.diabet.2015.11.001     Document Type: Editorial

References (24)

1. Salmela P.I., Sotaniemi E.A., Niemi M., Mäentausta O. Liver function tests in diabetic patients. Diabetes Care 1984, 7:248-254.
2. Forlani G., Di Bonito P., Mannucci E., Capaldo B., Genovese S., Orrasch M., et al. Prevalence of elevated liver enzymes in type 2 diabetes mellitus and its association with the metabolic syndrome. J Endocrinol Invest 2008, 31:146-152.
3. Tarantino G., Saldalamacchia G., Conca P., Arena A. Nonalcoholic fatty liver disease: further expression of the metabolic syndrome. J Gastroenterol Hepatol 2007, 22:293-303.
4. Petit J.-M., Guiu B., Masson D., Duvillard L., Jooste V., Buffier P., et al. Specifically PNPLA3-mediated accumulation of liver fat in obese patients with type 2 diabetes. J Clin Endocrinol Metab 2010, 95:E430-E436.
5. Leiter L.A., Forst T., Polidori D., Balis D.A., Xie J., Sha S. Effect of canagliflozin on liver function tests in patients with type 2 diabetes. Diabetes Metab 2015 doi: 10.1016/j.diabet.2015.10.003.
6. Stenlöf K., Cefalu W.T., Kim K.-A., Alba M., Usiskin K., Tong C., et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 2013, 15:372-382.
7. Forst T., Guthrie R., Goldenberg R., Yee J., Vijapurkar U., Meininger G., et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone. Diabetes Obes Metab 2014, 16:467-477.
8. Ueno T., Sugawara H., Sujaku K., Hashimoto O., Tsuji R., Tamaki S., et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 1997, 27:103-107.
9. Hickman I.J., Jonsson J.R., Prins J.B., Ash S., Purdie D.M., Clouston A.D., et al. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut 2004, 53:413-419.
10. Vilar-Gomez E., Martinez-Perez Y., Calzadilla-Bertot L., Torres-Gonzalez A., Gra-Oramas B., Gonzalez-Fabian L., et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 2015, 149:367-378. [e5; quiz e14-5].
11. Zelber-Sagi S., Kessler A., Brazowsky E., Webb M., Lurie Y., Santo M., et al. A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2006, 4:639-644.
12. Mattar S.G., Velcu L.M., Rabinovitz M., Demetris A.J., Krasinskas A.M., Barinas-Mitchell E., et al. Surgically-induced weight loss significantly improves nonalcoholic fatty liver disease and the metabolic syndrome. Ann Surg 2005, 242:610-617. [discussion 618-20].
13. Bugianesi E., Moscatiello S., Ciaravella M.F., Marchesini G. Insulin resistance in nonalcoholic fatty liver disease. Curr Pharm Des 2010, 16:1941-1951.
14. Gariani K., Philippe J., Jornayvaz F.R. Nonalcoholic fatty liver disease and insulin resistance: from bench to bedside. Diabetes Metab 2013, 39:16-26.
15. Mazza A., Fruci B., Garinis G.A., Giuliano S., Malaguarnera R., Belfiore A. The role of metformin in the management of NAFLD. Exp Diabetes Res 2012, 2012:716404.
16. Tiikkainen M., Häkkinen A.-M., Korsheninnikova E., Nyman T., Mäkimattila S., Yki-Järvinen H. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 2004, 53:2169-2176.
17. Loomba R., Lutchman G., Kleiner D.E., Ricks M., Feld J.J., Borg B.B., et al. Clinical trial: pilot study of metformin for the treatment of nonalcoholic steatohepatitis. Aliment Pharmacol Ther 2009, 29:172-182.
18. Musso G., Cassader M., Rosina F., Gambino R. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in nonalcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia 2012, 55:885-904.
19. Scheen A.J., Paquot N. Revisited: a critical review of the benefit/risk balance in 'at-risk' patients with type 2 diabetes. Diabetes Metab 2013, 39:179-190.
20. Ono M., Ikegami H., Fujisawa T., Nojima K., Kawabata Y., Nishino M., et al. Improvement of liver function parameters in patients with type 2 diabetes treated with thiazolidinediones. Metabolism 2005, 54:529-532.
21. Aghamohammadzadeh N., Niafar M., Dalir Abdolahinia E., Najafipour F., Mohamadzadeh Gharebaghi S., Adabi K., et al. The effect of pioglitazone on weight, lipid profile and liver enzymes in type 2 diabetic patients. Ther Adv Endocrinol Metab 2015, 6:56-60.
22. Promrat K., Lutchman G., Uwaifo G.I., Freedman R.J., Soza A., Heller T., et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatol Baltim Md 2004, 39:188-196.
23. Belfort R., Harrison S.A., Brown K., Darland C., Finch J., Hardies J., et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006, 355:2297-2307.
24. Silva T.E., Colombo G., Schiavon L.L. Adiponectin: a multitasking player in the field of liver diseases. Diabetes Metab 2014, 40:95-107.